MGMT and glioblastoma: A phase III trial of an individualized dendritic cell vaccine (DCVax-L) combined with standard treatment enhanced median overall survival in newly diagnosed and recurrent GBM patients, especially those in the methylated MGMT subgroup (Liau et al. 2023).